Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.39 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23228809 | 0.89 | SLC6A2 (0.46) | SLC6A2SLC6A4ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21656871 | 0.89 | RAB9A (0.44) | LPAR1LPAR5IGFBP3 | |
| SCHEMBL21657031 | 0.88 | PARP10 (0.46) | SLC6A2SLC6A4LPAR1LPAR5IGFBP3 | |
| SCHEMBL21656908 | 0.87 | ALDH1A1 (0.46) | ALDH1A1HPGDLPAR1LPAR5KMT2A | |
| SCHEMBL21656877 | 0.86 | HPGD (0.55) | SLC6A2SLC6A4ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21657024 | 0.86 | ALDH1A1 (0.36) | ALDH1A1HPGDLPAR1LPAR5 | |
| SCHEMBL21628755 | 0.84 | SLC6A2 (0.51) | SLC6A2SLC6A4ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21656657 | 0.83 | PTGER4 (0.35) | SLC6A2SLC6A4ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21628891 | 0.81 | SLC6A2 (0.52) | SLC6A2SLC6A4ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL20470550 | 0.79 | RAB9A (0.42) | SLC6A4ALDH1A1HPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591289-B2 | Aromatic compounds | AHR, TYR, MUSK | SLC6A2 3104/4885SLC6A4 3517/4885ALDH1A1 900/4885 |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | SLC6A2 2765/4885SLC6A4 3395/4885ALDH1A1 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.